Talnetant
Alternative Names: SB 223242; SB 223412; SB 223412A; Talnetant hydrochlorideLatest Information Update: 07 Feb 2008
At a glance
- Originator GlaxoSmithKline
- Class Irritable bowel syndrome therapies
- Mechanism of Action Neurokinin 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Schizophrenia
- Discontinued Chronic obstructive pulmonary disease; Cough; Irritable bowel syndrome; Overactive bladder; Urinary incontinence
Most Recent Events
- 30 May 2007 Data presented at the Digestive Disease Week-2007 (DDW-2007) have been added to the Digestive system disorders therapeutic trials section ,
- 14 May 2007 Talnetant is still in phase II trials for schizophrenia in the US
- 15 Dec 2005 Discontinued - Phase-II for Irritable bowel syndrome in United Kingdom (unspecified route)